Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma

International Journal of Cancer

Volumn 99, Issue 1, 2002, Pages 63-67

  Whiteman, David C ^a   Zhou, Xiao Ping ^b,c,d   Cummings, Margaret C ^e   Pavey, Sandra ^a   Hayward, Nicholas K ^a   Eng, Charis ^b,c,d  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

10q; Melanoma; P53; PTEN; Skin

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER GROWTH; CHROMOSOME 10Q; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA; MITOSIS INDEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN CARCINOGENESIS; TUMOR SUPPRESSOR GENE;

AGED; AGED, 80 AND OVER; CELL NUCLEUS; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MELANOMA; MIDDLE AGED; PHOSPHORIC MONOESTER HYDROLASES; PTEN PHOSPHOHYDROLASE; RISK FACTORS; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0036568378     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10294     Document Type: Article

References (51)

1. Localization of the gene for Cowden disease to 10q22-23
2. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome
3. Role of MMAC1 mutations in early onset breast cancer: Causative in association with Cowden's syndrome and excluded in BRCA1-negative cases
4. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation
5. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome
6. Germline and germline mosaic mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arterio-venous malformations and lipomatosis
7. Association of germline mutation in the PTEN tumour suppressor gene and a subset of Proteus and Proteus-like syndromes
8. Expression of PTEN protein in human embryonic development
9. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger phosphoinositol 3,4,5-triphosphate
10. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
11. 1 growth arrest in glioma cells
12. 1 cell cycle arrest in human glioblastoma cells
13. PTEN is inversely correlated with the cell survival factor PKB/Akt and is inactivated by diverse mechanisms in haematologic malignancies
14. 1 arrest followed by apoptosis
15. 1 arrest by down regulating cyclin D1 via its protein phosphatase activity and up regulating p27 via its lipid phosphatase activity
16. PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and independent pathways
17. Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death
18. Possible involvement of the chromosome region 10q24-26 in early stages of melanocytic neoplasia
19. Growth factor and cytogenetic abnormalities in cultured nevi and malignant melanomas
20. Cytogenetic analysis of melanocytes from premalignant nevi and melanomas
21. Cytogenetic analysis in melanoma and nevi
22. Easton DFBCLC. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers
23. Loss of heterozygosity for 10q22-10qter in malignant melanoma progression
24. Mutations of the CDKN2/ p161nk4A gene in Australian melanoma kindreds
25. Chromosome 10 allelic loss in malignant melanoma
26. 10q deletions in metastatic cutaneous melanoma
27. The chromosome 10 monosomy common in human melanomas results from loss of two separate tumor suppressor loci
28. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines
29. Identification of PTEN/MMAC1 mutations in uncultured melanomas and melanoma cell lines
30. The PTEN tumour suppressor gene and malignant melanoma
31. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines
32. Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies
33. Identification of PTEN mutations in metastatic melanoma specimens
34. Allelic losses on chromosome arm 10q and mutation of the PTEN (MMAC1) tumour suppressor gene in primary and metastatic malignant melanomas
35. PTEN/MMAC1 in malignant melanoma and its importance for tumor progression
36. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation
37. p53 expression and risk factors for cutaneous melanoma: A case-control study
38. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast
39. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers
40. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells
41. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors
42. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin DI expression, in primary epithelial ovarian carcinomas
43. p53 protein expression in nevi and melanomas
44. Prognostic significance of p53 over-expression in thin melanomas
45. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer
46. Changes in endometrial PTEN expression throughout the human menstrual cycle
47. Heterogeneous lack of expression of tumour suppressor PTEN protein in human neoplastic tissues, Eur J Cancer
48. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation
49. Regulation of PTEN transcription by p53
50. Allelic loss of 10q22-23, the PTEN tumour suppressor gene locus, in Barrett-associated esophageal adenocarcinoma
51. Molecular identification of latent precancers in histologically normal endometrium